Japanese healthcare products and services company PHC has joined forces with US-based oncology firm NovaScan to explore the feasibility of the latter’s investigational ex vivo (outside the body) medical device, dubbed MarginScan.
The companies will jointly explore the feasibility of MarginScan to facilitate the comprehensive real-time margin detection of non-melanoma skin cancers (NMSC).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
PHC in vitro diagnostics division director Hiroyuki Tokunaga said: “We look forward to collaborating with NovaScan to provide high-value-added solutions in the pathology diagnostics field, leveraging our expertise in highly reliable medical device development.”
MarginScan is expected to be used in Mohs surgery procedures for the treatment of skin cancer. Mohs micrographic surgery is a surgical excision technique used for the detection of the presence or absence of a tumour in the margins of a surgical excision.
The device is also anticipated to reduce patient morbidity besides enhancing outcomes for both patients and clinicians.
The partnership will leverage PHC’s manufacturing expertise and NovaScan’s advanced technology to identify carcinoma tissue.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNovaScan CEO Craig Davis said: “Our platform technology enables in vivo and ex vivo cancer detection, in real-time and without expensive capital equipment or the need for steep clinician learning curves.
“We believe that MarginScan has the potential to be employed in standard-of-care procedures for the most common cancers in the world.”
